These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 24629489)

  • 21. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas.
    Izeradjene K; Combs C; Best M; Gopinathan A; Wagner A; Grady WM; Deng CX; Hruban RH; Adsay NV; Tuveson DA; Hingorani SR
    Cancer Cell; 2007 Mar; 11(3):229-43. PubMed ID: 17349581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice.
    Grippo PJ; Fitchev PS; Bentrem DJ; Melstrom LG; Dangi-Garimella S; Krantz SB; Heiferman MJ; Chung C; Adrian K; Cornwell ML; Flesche JB; Rao SM; Talamonti MS; Munshi HG; Crawford SE
    Gut; 2012 Oct; 61(10):1454-64. PubMed ID: 22234980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma.
    Hashimoto D; Arima K; Yokoyama N; Chikamoto A; Taki K; Inoue R; Kaida T; Higashi T; Nitta H; Ohmuraya M; Hirota M; Beppu T; Baba H
    Pancreas; 2016 Sep; 45(8):1111-4. PubMed ID: 26967456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins.
    Kim J; Reber HA; Dry SM; Elashoff D; Chen SL; Umetani N; Kitago M; Hines OJ; Kazanjian KK; Hiramatsu S; Bilchik AJ; Yong S; Shoup M; Hoon DS
    Gut; 2006 Nov; 55(11):1598-605. PubMed ID: 16682430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice.
    Grippo PJ; Nowlin PS; Demeure MJ; Longnecker DS; Sandgren EP
    Cancer Res; 2003 May; 63(9):2016-9. PubMed ID: 12727811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peritoneal Cell-Free Tumor DNA is a Biomarker of Locoregional and Peritoneal Recurrence in Resected Pancreatic Ductal Adenocarcinomas.
    Leick KM; Tomanek-Chalkley A; Coleman KL; Chan CHF
    Ann Surg Oncol; 2023 Oct; 30(11):6652-6660. PubMed ID: 37303025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KRAS mutation allele frequency threshold alters prognosis in right-sided resected pancreatic cancer.
    Nauheim D; Moskal D; Renslo B; Chadwick M; Jiang W; Yeo CJ; Nevler A; Bowne W; Lavu H
    J Surg Oncol; 2022 Aug; 126(2):314-321. PubMed ID: 35333412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The conditional expression of KRAS G12D in mouse pancreas induces disorganization of endocrine islets prior the onset of ductal pre-cancerous lesions.
    Gout J; Pommier RM; Vincent DF; Ripoche D; Goddard-Léon S; Colombe A; Treilleux I; Valcourt U; Tomasini R; Dufresne M; Bertolino P; Bartholin L
    Pancreatology; 2013; 13(3):191-5. PubMed ID: 23719586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer.
    McIntyre CA; Grimont A; Park J; Meng Y; Sisso WJ; Seier K; Jang GH; Walch H; Aveson VG; Falvo DJ; Fall WB; Chan CW; Wenger A; Ecker BL; Pulvirenti A; Gelfer R; Zafra MP; Schultz N; Park W; O'Reilly EM; Houlihan SL; Alonso A; Hissong E; Church GM; Mason CE; Siolas D; Notta F; Gonen M; Dow LE; Jarnagin WR; Chandwani R
    Cancer Cell; 2024 Sep; 42(9):1614-1629.e5. PubMed ID: 39214094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy.
    Sugimori M; Sugimori K; Tsuchiya H; Suzuki Y; Tsuyuki S; Kaneta Y; Hirotani A; Sanga K; Tozuka Y; Komiyama S; Sato T; Tezuka S; Goda Y; Irie K; Miwa H; Miura Y; Ishii T; Kaneko T; Nagahama M; Shibata W; Nozaki A; Maeda S
    Cancer Sci; 2020 Jan; 111(1):266-278. PubMed ID: 31746520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of Recurrence With KRAS Mutational Burden Using Ultrasensitive Digital Polymerase Chain Reaction of Radial Resection Margin of Resected Pancreatic Ductal Adenocarcinoma.
    Kim SJ; Kim MJ; Han JS; Sung YN; An S; Lee JH; Song KB; Hwang DW; Lee SS; Cho H; Kim SC; Eshleman JR; Hong SM
    Pancreas; 2019 Mar; 48(3):400-411. PubMed ID: 30747828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of microRNA-218 in human pancreatic ductal adenocarcinoma and its correlation with tumor progression and patient survival.
    Zhu Z; Xu Y; Du J; Tan J; Jiao H
    J Surg Oncol; 2014 Feb; 109(2):89-94. PubMed ID: 24166773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.
    Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
    Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repeat pancreatectomy for pancreatic ductal cancer recurrence in the remnant pancreas after initial pancreatectomy: is it worthwhile?
    Miyazaki M; Yoshitomi H; Shimizu H; Ohtsuka M; Yoshidome H; Furukawa K; Takayasiki T; Kuboki S; Okamura D; Suzuki D; Nakajima M
    Surgery; 2014 Jan; 155(1):58-66. PubMed ID: 24238124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues.
    Aichler M; Seiler C; Tost M; Siveke J; Mazur PK; Da Silva-Buttkus P; Bartsch DK; Langer P; Chiblak S; Dürr A; Höfler H; Klöppel G; Müller-Decker K; Brielmeier M; Esposito I
    J Pathol; 2012 Apr; 226(5):723-34. PubMed ID: 21984419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Alterations Associated with DNA Repair in Pancreatic Adenocarcinoma Are Associated with Sites of Recurrence.
    Ferguson MD; Dong L; Wan J; Deneve JL; Dickson PV; Behrman SW; Shibata D; Martin MG; Glazer ES
    J Gastrointest Cancer; 2019 Jun; 50(2):285-291. PubMed ID: 29427136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma.
    Lee J; Jang KT; Ki CS; Lim T; Park YS; Lim HY; Choi DW; Kang WK; Park K; Park JO
    Cancer; 2007 Apr; 109(8):1561-9. PubMed ID: 17354229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Results of surgical treatment in ampullary and pancreatic carcinoma and its prognostic parameters after R0-resection].
    Ridwelski K; Meyer F; Schmidt U; Lippert H
    Zentralbl Chir; 2005 Aug; 130(4):353-61. PubMed ID: 16103961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium.
    Lüttges J; Schlehe B; Menke MA; Vogel I; Henne-Bruns D; Klöppel G
    Cancer; 1999 Apr; 85(8):1703-10. PubMed ID: 10223563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.